Skip to main content
. Author manuscript; available in PMC: 2019 Feb 4.
Published in final edited form as: Cancer Chemother Pharmacol. 2014 Sep 3;74(5):955–967. doi: 10.1007/s00280-014-2569-7

Fig. 1.

Fig. 1

Perifosine plasma concentration–time profile. The data were from 24 patients who received perifosine from dose level l to level 5 at cycle 1. Filled circle level l (n = 3), open circle level 2 (n = 3), filled square level 3 (n = 8), open square level 4 (n = 7), filled triang le level 5 (n = 3). Median concentrations are shown